 Connection
Peter Gottlieb to Clinical Trials as Topic
This is a "connection" page, showing publications Peter Gottlieb has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.748 |
|
|
|
-
Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care. 2009 Oct; 32(10):1769-82.
Score: 0.230
-
Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia. 2020 04; 63(4):885-886.
Score: 0.117
-
Michels AW, Gottlieb PA. Learning From Past Failures of Oral Insulin Trials. Diabetes. 2018 07; 67(7):1211-1215.
Score: 0.105
-
Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA. Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes. 2018 07; 67(7):1216-1225.
Score: 0.104
-
Gottlieb P, Utz PJ, Robinson W, Steinman L. Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. Clin Immunol. 2013 Dec; 149(3):297-306.
Score: 0.075
-
Gottlieb PA, Hayward AR. Cytokine and immunosuppressive therapies of type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2002 Jun; 31(2):477-95.
Score: 0.035
-
Gottlieb PA, Eisenbarth GS. Diagnosis and treatment of pre-insulin dependent diabetes. Annu Rev Med. 1998; 49:391-405.
Score: 0.025
-
Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015 Oct; 38(10):1975-85.
Score: 0.022
-
Loechelt BJ, Green M, Gottlieb PA, Blumberg E, Weinberg A, Quinlan S, Baden LR. Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders. J Pediatric Infect Dis Soc. 2015 Sep; 4(3):198-204.
Score: 0.020
-
Haller MJ, Gottlieb PA, Schatz DA. Type 1 diabetes intervention trials 2007: where are we and where are we going? Curr Opin Endocrinol Diabetes Obes. 2007 Aug; 14(4):283-7.
Score: 0.012
-
Catane R, Schlanger S, Weiss L, Penchas S, Fuks Z, Treves AJ, Gottlieb P, Fridkin M. Toxicology and antitumor activity of tuftsin. Ann N Y Acad Sci. 1983; 419:251-60.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|